Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC - What Difference Does it Make?

导出 LinkOut

翻译打印收藏纠错

第一作者： Hendrik,Eggers

第一单位： Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

作者： Hendrik,Eggers ^[1] ; Lea,Häbel ^[2] ; Arnold,Ganser ^[1] ; Viktor,Grünwald ^[2] ; Roland,Merten ^[1] ; Athanasia,Warnecke ^[2] ; Martin,Durisin ^[1] ; Philipp,Ivanyi ^[3]

作者单位： Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. ^[1] Comprehensive Cancer Center Hannover, Claudia von Schilling Center, Hannover Medical School, Hannover, Germany. ^[2] Interdisciplinary GU Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany (Current position). ^[3] Department of Radiotherapy, Hannover Medical School, Hannover, Germany. ^[4] Department of Otorhinolaryngology, Hannover Medical School, Hannover, Germany. ^[5]

关键词 Anti-EGFR R/M-HNSCC cetuximab head and neck cancer treatment

主题词人类(Humans);头颈部肿瘤(Head and Neck Neoplasms);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1080/07357907.2022.2134414

PMID 36239419

发布时间 2023-01-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交